Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PREP | P48147 | 3/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | GFER | P55789 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | CTRB1 | P17538 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2806846 | 0.82 | SMN1; SMN2 (0.47) | ALDH1A1L3MBTL1SIGMAR1 | |
| SCHEMBL4016879 | 0.82 | SMN1; SMN2 (0.47) | ALDH1A1L3MBTL1SIGMAR1 | |
| SCHEMBL2007920 | 0.79 | ALDH1A1 (0.54) | KMT2AALDH1A1TSHRSIGMAR1 | |
| SCHEMBL3639676 | 0.75 | FKBP1A (0.48) | KMT2AALDH1A1SIGMAR1 | |
| SCHEMBL22285161 | 0.75 | ENPP2 (0.57) | ALDH1A1L3MBTL1SIGMAR1 | |
| SCHEMBL190556 | 0.75 | ENPP2 (0.57) | ALDH1A1L3MBTL1SIGMAR1 | |
| SCHEMBL13434275 | 0.74 | SMN1; SMN2 (0.54) | KMT2AALDH1A1NPSR1L3MBTL1 | |
| SCHEMBL7801189 | 0.73 | ENPP2 (0.55) | TSHRL3MBTL1SIGMAR1 | |
| SCHEMBL876820 | 0.73 | SIGMAR1 (0.53) | SIGMAR1 | |
| SCHEMBL2273359 | 0.72 | SMN1; SMN2 (0.57) | KMT2AALDH1A1NPSR1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2173709-A2 | METHODS AND INTERMEDIATES FOR SYNTHESIS OF SELECTIVE DPP-IV INHIBITORS | Phenomix Corporation (US) | 2010-04-14 | — | — | EP | disclosed |
| US-20100087658-A1 | METHODS AND INTERMEDIATES FOR SYNTHESIS OF SELECTIVE DPP-IV INHIBITORS | PHENOMIX CORPORATION (US) | 2010-04-08 | — | — | US | disclosed |
| CN-101679238-A | methods and intermediates for synthesis of selective dpp-iv inhibitors | PHENOMIX CORP | 2010-03-24 | — | — | CN | disclosed |
| WO-2009094462-A1 | A CRYSTALLINE SYNTHETIC INTERMEDIATE FOR PYRROLIDIN-3-YL-GLYCYLAMINOALKYLBORONATES | PHENOMIX CORPORATION (US) | 2009-07-30 | — | — | WO | disclosed |
| WO-2008109681-A2 | METHODS AND INTERMEDIATES FOR SYNTHESIS OF SELECTIVE DPP-IV INHIBITORS | PHENOMIX CORPORATION (US) | 2008-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100087658-A1 | METHODS AND INTERMEDIATES FOR SYNTHESIS OF SELECTIVE DPP-IV INHIBITORS | DPP4, DPP3, DPP7 | PREP 19/4885KMT2A 3846/4885GFER 3248/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.